Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.

Abstract: A method, system, apparatus, and/or device to align a miniaturized impedance sensor over the muscular-walled tube of a user. The method, system, apparatus, and/or device may include: a band comprising a shape, size, and flexibility designed for attaching the band to a body part of a user, where the body part includes a dermal layer and a muscular-walled tube; a miniaturized impedance sensor embedded in the band and positioned in the band to be pressed against a portion of the body part adjacent to the muscular-walled tube as the user wears the band, where the miniaturized impedance sensor may include two or more miniaturized electrode strips or an array of miniaturized electrode pillars; and an alignment device embedded in the band and configured in the band to align the miniaturized impedance sensor over the muscular-walled tube as the user wears the band.

Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: A washing toilet seat assembly includes a toilet seat and a housing configured to be coupled to a toilet bowl to support the toilet seat about a pivot axis. The housing includes a cartridge interface and a cover moveable between an open position allowing access to the cartridge interface and a closed position blocking access to the cartridge interface. The washing toilet seat assembly further includes a cartridge removably coupled to the cartridge interface, the cartridge including a dispensable solution, and a spray wand moveably supported by at least one of the toilet seat or the housing. The spray wand is in fluid communication with the cartridge to dispense the dispensable solution, and the spray want is configured to dispense the dispensable solution during operation of the washing toilet seat assembly as a user sits on the toilet seat.

Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

Abstract: An assembly for delivering an implantable medical device, the assembly includes an implantable medical device including an attachment feature and a delivery device that is adapted to releasably secure the implantable medical device, the delivery device including an attachment element adapted to create an interference fit with the attachment feature of the implantable medical device. The delivery device is adapted to enable a user to selectively disengage the interference fit between the attachment element of the delivery device and the attachment feature of the implantable medical device with a short linear motion when the delivery device is positioned proximate a delivery site for the implantable medical device.

Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-ol, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.

Abstract: A quick-release latch may include a male component and a female component. The male component may include an insertable male portion comprising a top wall, a bottom wall, and one or more sidewalls. The male component may also include a first strap attachment portion defining a first plurality of strap openings each having a laterally extending strap slot and a mouth positioned off-center of and providing exterior access to the respective strap slot. The female component may include a female receptacle portion comprising a top wall, a bottom wall, and one or more sidewalls collectively forming a receptacle configured to receive and releasably lock to the insertable male portion of the male component. The top wall of the female receptacle may include a cantilever wall partially surrounded by one or more slots. The cantilever wall may extend proximate a same plane as the top wall.

Abstract: A computing device includes a hardware switch that is activated when a primary Basic Input/Output System (BIOS) of a first BIOS chip of the device fails to load an Operating System (OS) image from an OS partition of a hard drive. The switch passes control to a backup BIOS that executes from a backup BIOS chip. The backup BIOS loads a recovery image from BIOS recovery partition of the hard drive, which causes a reflash application to execute from the recovery image. Reflash application obtains a recovery BIOS from the BIOS recovery partition of the hard drive, reflashes/writes the recovery BIOS onto the first BIOS chip and reboots the device. Following reboot of the device, recovery BIOS loads the OS image from the OS partition, and recovery BIOS becomes the primary BIOS on the first BIOS chip of the device.

Abstract: A method, system, apparatus, and/or device for measuring a physiological condition of a user. The method, system, apparatus, and/or device may include: a band configured to attach to a body part of a user; a housing coupled to the band; a processing device integrated into the band or disposed within the housing; an interface integrated into the band or disposed within the housing; and a miniaturized impedance sensor.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: The invention relates to pharmaceutical compositions comprising, compounds of Formula Q: wherein W is —N(H)—, or —N(CH3)—, and Y is —C(?O)— or —O—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.

Abstract: An optical system for receiving light scanned from different light origination locations in space can include a Liquid Crystal (LC) waveguide (LCW), including first and second LCW light ports. A beamsteering LC electrode can be included in or coupled to the LCW and can be configured to vary a receiving direction of light received at the second LCW light port in response to a varying electrical input signal applied to the LC electrode to scan receiving of light at the second LCW light port from different light origination locations in space. A photodetector can be optically coupled to the first LCW light port, such as to detect waveguided light from different light origination locations in space received in response to the varying electrical input signal applied to the first LC electrode. Ranger, bright-spot locking, laser detection, direct detect and coherent lidar, wavelength detection, and other techniques and use cases are possible.

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: A method and apparatus are for determining a medical biomarker indicative of a neurodegenerative disease. The method includes receiving motion data from a sensor held or mounted for rotation with a body part of the user during a repeated rotational motion of the body part. The motion data are provided relative to a frame of reference associated with the sensor. The motion data are processed to identify orientation in the frame of reference associated with the sensor of primary, secondary, and tertiary axes of rotation for the motion of the body part of the user, each of the primary, secondary and tertiary axes being mutually perpendicular to one another. A medical biomarker is extracted by analysing the rotational motion of the body part of the user about the primary, secondary and tertiary axes.

Abstract: A computer-implemented method performed at a health study management system collects health-related data from data sources, including sensors monitoring system users. A modular data ingestion subsystem includes interface modules adapted to receive health-related data from a respective type of data source. A modular data processing subsystem includes processing modules, processing health-related data to determine derived health indicators. The system receives configuration information for a health study using the health study management system, the configuration information specifying data collection activities, for collecting respective health-related data. The data collection activities include sensor-based data collection activities associated with a sensor type for collecting sensor data, and processing collected sensor data. The data ingestion subsystem and data processing subsystem are configured for the health study.

Abstract: A method, system, apparatus, and/or device to determine a condition of a user using a miniaturized collimator. The method, system, apparatus, and/or device may include: a carbon nanotube structure comprising a microtube that includes a set of aligned carbon nanotubes infiltrated by carbon and a through-channel, the carbon nanotube structure having a defined height to through-channel width aspect ratio, where: the defined height to through-channel width aspect ratio is based on a defined collimation to diffraction ratio; the set of aligned carbon nanotubes infiltrated by carbon is configured to absorb a first portion of light that travels through the through-channel at a first angle and impinges a side of a first through-channel portion; and the set of aligned carbon nanotubes infiltrated by the carbon is configured to allow a second portion of the light that enters the through-channel at a second angle to pass through the through-channel.